General Catalyst's acquisition of Summa Health was unusual from the start. Through HATCo, it wasn't simply investing in healthcare technology but actually acquired an entire health system. Less than a year later, we're beginning to see what that model looks like in practice.

Summa recently announced that a number of General Catalyst-backed companies are being deployed across the health system, spanning both clinical and administrative operations. There is a lot that is compelling about this approach. Healthtech companies often spend years trying to navigate a traditional health system's complex procurement and implementation processes. General Catalyst has effectively created a testbed environment where technologies it has invested in can be deployed and evaluated at scale with remarkable efficiency.

Legal and Operational Realities

As healthcare counsel, what interests us is what this model looks like once it shifts from an investment strategy into day-to-day healthcare operations. When the owner of a health system also holds an economic interest in the companies providing its core technology, the distance between investor, vendor, and operator virtually disappears.

While that alignment can accelerate innovation, it also makes robust corporate governance, regulatory oversight, and compliance essential. Key areas that demand rigorous, objective evaluation include:

• Vendor Selection & Fair Market Value: Ensuring procurement processes, vendor contracts, and pricing structures withstand scrutiny regarding self-dealing and regulatory compliance.

• Conflicts of Interest: Managing overlapping fiduciary duties between healthtech portfolio companies and hospital operational management.

• Patient Data Privacy & Cybersecurity: Establishing clear boundaries around patient health data sharing, model training permissions, and HIPAA compliance across affiliated tech entities.

• Clinical Oversight & AI Accountability: Maintaining independent medical judgment when deploying automated or AI-driven tools in clinical decision-making.

Building the Right Framework for Innovation

As AI becomes deeply integrated into routine clinical and operational decisions, accountability becomes paramount: Who is independently evaluating the technology? Who is monitoring long-term performance and algorithmic drift? And who ultimately bears legal responsibility when a platform error impacts patient care?

This is not an argument against the model, which is innovative and holds tremendous potential for accelerating care delivery. General Catalyst may well have pioneered a far more efficient pathway to scale promising healthtech solutions. However, the faster and more integrated these platforms become, the more critical it is to establish clear legal, contractual, and governance frameworks around them.

At MDRXLaw, we counsel health systems, physician groups, healthtech ventures, and management organizations on corporate governance, vendor contracting, data privacy, and regulatory risk management. To discuss how emerging healthcare investment structures may impact your business, contact our healthcare legal team by phone at 212.668.0200 or via email at info@mdrxlaw.com.